Sander van Deventer, M.D., Ph.D. has served as a member of our board of directors since 2001. Dr. van Deventer has had a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world (Glybera). He currently is a General Partner at Forbion Capital Partners and Professor of Translational Gastroenterology Leiden University Medical Center. He is a member of the Boards of Argos Therapeutics (Durham, USA), Uniqure (Amsterdam, The Netherlands), Cardoz (Stockholm, Sweden) gICare (Montreal, Canada) en Hookipa (Vienna, Austria).
Dr. van Deventer was trained as an internist and board vertified gastroenterologist, received doctorate of philosophy from the University of Amsterdam, worked as a scientist at Rockefeller University and became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam in 1995. In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT; currently Uniqure), a gene therapy company that develops AAV-based gene therapy products. From 2001 until 2004, he chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. He has authored more than 500 peer review scientific papers, and supervised more than 40 PhD students.